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Background: CURRENT-OASIS 7 found no difference in 30-day outcomes between low and higher dose aspirin (ASA) groups post-AMI. The 
association of ASA dosing with long-term outcomes among contemporary AMI patients treated with PCI and dual antiplatelet therapy remains 
uncertain.
methods: Use of low vs. higher dose (<162 mg vs. ≥162 mg daily) ASA at discharge was studied among 6,045 AMI patients treated with PCI at 
209 U.S. hospitals in the TRANSLATE-ACS observational study from 4/2010-8/2012. We compared 6-month risks of MACE (composite of death, MI, 
stroke, or unplanned revascularization) and rehospitalization with bleeding between groups using multivariable Cox models.
results: Overall, 1808 patients (30%) received low dose ASA at discharge. Patients prescribed low dose ASA were older, more often had prior MI, 
stroke/TIA, or diabetes. Compared with higher dose patients, those prescribed low dose ASA had similar rates of STEMI (50.0% vs. 52.7%), but were 
more likely to receive bare metal stents (34.5% vs. 26.9%, p<0.001) or 2nd generation ADP inhibitors (prasugrel or ticagrelor) at discharge (31.8% 
vs. 27.7%, p=0.001). There were no significant differences in adjusted 6-month MACE and bleeding risks between patients discharged on low vs. 
higher dose ASA (Table).
conclusion: Low dose ASA is prescribed at discharge in less than one-third of PCI-treated AMI patients in the U.S. There was no significant 
difference in 6-month risks of cardiovascular events and bleeding between dosing groups.
 
